Tag: top employers

Latest articles

Promising Innovative Medicine designation for Novartis' targeted radioligand theragnostics in prostate cancer

Promising Innovative Medicine designation for Novartis’ targeted radioligand theragnostics in prostate cancer

Novartis has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation for 177Lu-PSMA-617, an investigational radioligand...
Positive Phase III results for Lynparza plus abiraterone in metastatic prostate cancer

Positive Phase III results for Lynparza plus abiraterone in metastatic prostate cancer

Positive high-level results from the PROpel Phase III trial have shown that AstraZeneca and MSD’s Lynparza (olaparib), in combination with abiraterone, demonstrated a significant improvement in...
AstraZeneca invests in Imperial College spin-off, VaxEquity

AstraZeneca invests in Imperial College spin-off VaxEquity

AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisation of the proprietary self-amplifying RNA (saRNA) therapeutics platform developed...

Popular articles

Image of a person descending a ladder over coronavirus to show New Normal, New Thinking: Life Post COVID-19

New Normal, New Thinking: Life Post COVID-19

New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Promising Innovative Medicine designation for Novartis' targeted radioligand theragnostics in prostate cancer

Promising Innovative Medicine designation for Novartis’ targeted radioligand theragnostics in prostate cancer

Novartis has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation for 177Lu-PSMA-617, an investigational radioligand...
UK market access and the opportunities for pharma

UK market access and the opportunities for pharma

The UK market access environment faces a time of change – the result of the convergence of several major drivers of reform. The COVID-19...
Positive Phase III results for Lynparza plus abiraterone in metastatic prostate cancer

Positive Phase III results for Lynparza plus abiraterone in metastatic prostate cancer

Positive high-level results from the PROpel Phase III trial have shown that AstraZeneca and MSD’s Lynparza (olaparib), in combination with abiraterone, demonstrated a significant improvement in...
COVID-19 antibody drug Ronapreve to be rolled out to vulnerable patients

COVID-19 antibody drug Ronapreve rolled out to vulnerable patients

Thousands of vulnerable NHS patients in hospital due to COVID-19 are set to benefit from a ground-breaking new antibody treatment Ronapreve. The drug is...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription